Compare · DFTX vs SMFL
DFTX vs SMFL
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Smart for Life Inc. (SMFL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and SMFL operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $2.51B.
- Over the past year, DFTX is up 196.5% and SMFL is up 0.0% - DFTX leads by 196.5 points.
- DFTX has hit the wire 3 times in the past 4 weeks while SMFL has been quiet.
- DFTX has more recent analyst coverage (4 ratings vs 0 for SMFL).
- Company
- Definium Therapeutics Inc.
- Smart for Life Inc.
- Price
- $23.02-2.29%
- $0.83-17.00%
- Market cap
- $2.51B
- -
- 1M return
- -0.95%
- +0.00%
- 1Y return
- +196.46%
- +0.00%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2023
- News (4w)
- 3
- 0
- Recent ratings
- 4
- 0
Smart for Life Inc.
Smart for Life, Inc. acquires, develops, manufactures, operates, markets, and sells nutraceutical and related products in the United States and internationally. It offers natural health and wellness meal replacement products, including nutrition bars, cookies, soups and shakes, vitamins, and supplements; dietary supplements; nutritional supplements for athletes and active lifestyle consumers comprising powders, tablets, and soft gels; and various nutritional supplements. It sells its products through online market platforms. The company was formerly known as Bonne Santé Group, Inc. and changed its name to Smart for Life, Inc. in August 2021. Smart for Life, Inc. was founded in 2002 and is based in Miami, Florida.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 10-Q filed by Definium Therapeutics Inc.
- Definium Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
- Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Latest SMFL
- SEC Form 10-Q filed by Smart for Life Inc.
- SEC Form 10-Q filed by Smart for Life Inc.
- SEC Form 25-NSE filed by Smart for Life Inc.
- Smart for Life Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Amendment: SEC Form SC 13G/A filed by Smart for Life Inc.
- SEC Form NT 10-Q filed by Smart for Life Inc.
- Smart for Life Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
- Smart for Life Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Smart for Life Reports Significant Balance Sheet Improvement; Achieves Over $9.4 Million in Positive Net Stockholders' Equity Following Successful Restructuring Efforts
- Smart for Life Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing